CRISPR THERAPEUTICS AG (CRSP:NASDAQ)
$55.54 -2.15 (-3.7268%)
Analysed CRISPR THERAPEUTICS AG (CRSP:NASDAQ) News Sources
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy?
21-04-2026
fool.com
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
21-04-2026
yahoo.com
Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Share Price Performance
21-04-2026
yahoo.com
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
16-04-2026
yahoo.com
CRISPR Therapeutics Touts “Second Phase” After Casgevy, Eyes 6 Data Readouts in 6–12 Months
13-04-2026
marketbeat.com
2 Billion Reasons to Love CRISPR Therapeutics Right Now
13-04-2026
fool.com
Three Best Genomics Stocks for Your Portfolio in 2026
13-04-2026
yahoo.com
Colossal’s Ben Lamm Says Invasive Species Is a $5.4 Trillion Problem. Here’s His Solution
12-04-2026
247wallst.com
Is CRISPR Therapeutics (CRSP) Pricing In Too Much Hope After Recent Share Price Recovery
12-04-2026
yahoo.com
How Investors May Respond To CRISPR Therapeutics (CRSP) One-Time Cardiovascular Gene-Editing Ambitions
12-04-2026
yahoo.com
What is the current price of CRISPR THERAPEUTICS AG (CRSP:NASDAQ)?
The current price of CRISPR THERAPEUTICS AG (CRSP:NASDAQ) is $55.54.
CRISPR THERAPEUTICS AG (CRSP:NASDAQ) absolute price change since previous trading day?
The absolute price change of CRISPR THERAPEUTICS AG (CRSP:NASDAQ) since the previous trading day is $-2.15.
CRISPR THERAPEUTICS AG (CRSP:NASDAQ) percentage price change since previous trading day?
The percentage price change of CRISPR THERAPEUTICS AG (CRSP:NASDAQ) since the previous trading day is -3.7268%.
What is the most recent average sentiment score for CRISPR THERAPEUTICS AG (CRSP:NASDAQ)?
The most recent average sentiment score for CRISPR THERAPEUTICS AG (CRSP:NASDAQ) is 89 out of 100.
What is the most recent average sentiment for CRISPR THERAPEUTICS AG (CRSP:NASDAQ)?
The most recent sentiment for CRISPR THERAPEUTICS AG (CRSP:NASDAQ) is .
SEC-8K** Filing Available For CRISPR THERAPEUTICS AG (CRSP:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.